Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI may outsmart current system for liver transplant priority

NCT ID NCT06675604

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This European study is collecting health data from 4,500 adults listed for liver transplantation across 50 centers. The goal is to design and test new AI-based models that predict which patients are most likely to die or become too sick for transplant while waiting. If accurate, these models could replace the current scoring system and improve fairness in organ allocation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to fairer and more accurate liver transplant allocation, saving more lives by prioritizing the sickest patients.
What could go wrong
This is an observational data-collection study, not a treatment trial. The AI models may not improve predictions enough to change current practices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 4,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults patients listed for : * Decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset 1) * Other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc…) (subset 2) * Hepato-cellular carcinoma as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3)

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult \[age 18;70\] patients listed for: * decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset 1) OR * other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc…) (subset 2) OR * HCC\* as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3). (HCC diagnosed on Barcelona/EASL criteria or histologically proven. HCC meeting or not Milan criteria, as per center practice.) * Patients registered on national waiting lists under the MELD offering schemes, regardless of extra MELD points and MELD exceptions are affected or not. * Patient (or trusted person, family member or close relation, if the patient is unable to be informed) who has been informed and did not express opposition to data collection (\*Of note, enrolment of patients with T1 tumors (1 single tumor \< 2 cm diameter) not amenable to loco-regional therapies because of decompensation, and prioritized under the MELD system, will be allowed in Subset 1.) Exclusion Criteria: * Tumor vascular invasion (portal or hepatic veins) evidenced by imaging at pre transplantation work-up, including portal vein thrombosis stage 1 * Extra-hepatic metastasis of HCC, as assessed by sectional imaging, functional imaging (18 FDG PET CT/MRI) or histologically proven * Patients who are under safeguard of justice or tutorship or curatorship * Patient on AME (state medical aid) * Participation to LEOPARD PVC 1 study of WP2

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decompensated liver cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cholangitis, Sclerosing chronic liver failure cirrhosis of liver hepatocellular carcinoma primary biliary cholangitis primary sclerosing cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Decompensated liver cirrhosis Hepato-cellular carcinoma Primary biliary cholangitis Primary sclerosing cholangitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    53 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aou Policlinico di Bari

    RECRUITING

    Bari, Italy

  • Azienda Ospedale - Università Padova

    RECRUITING

    Padova, Italy

  • Azienda Ospedaliera San Camillo-Forlanini

    RECRUITING

    Rome, Italy

  • Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli

    RECRUITING

    Naples, Italy

  • Azienda Ospedaliero Universitaria Policlinico Umberto I di Roma

    RECRUITING

    Roma, Italy

  • CHRU Huriez Lille, Department of Hepatology

    RECRUITING

    Lille, 59000, France

  • CHRU Montpellier Saint Eloi, Department of Hepatology

    RECRUITING

    Montpellier, 34295, France

  • CHRU Strasbourg, Chirurgie Hepato-bilio-pancreatique et transplantation hepatique Department

    RECRUITING

    Strasbourg, 67000, France

  • CHU Beaujon, Department of Hepatology

    RECRUITING

    Clichy, 92110, France

  • CHU Bordeaux Haut Levêque, Department of Hepatology

    RECRUITING

    Pessac, 33604, France

  • CHU Dijon, Department of Hepatology

    RECRUITING

    Dijon, 21069, France

  • CHU Jean Minjoz Besançon, Department of Hepatology

    RECRUITING

    Besançon, 25000, France

  • CHU L'Archet Nice, Department of Hepatology

    RECRUITING

    Nice, 06000, France

  • CHU La Pitié Salpêtrière, Department of Hepatology

    RECRUITING

    Paris, 75013, France

  • CHU La Timone AP-HM, Department of Hepatology

    RECRUITING

    Marseille, 13005, France

  • CHU Liège

    RECRUITING

    Liège, Belgium

  • CHU Lyon Croix Rousse, Department of Hepatology

    RECRUITING

    Lyon, 69004, France

  • CHU Paul Brousse, Department of Hepatology

    RECRUITING

    Villejuif, 94800, France

  • CHU Pontchaillou Rennes, Department of Hepatology

    RECRUITING

    Rennes, 35033, France

  • CHU Purpan Toulouse, Department of Hepatology

    RECRUITING

    Toulouse, 31059, France

  • CHU Trousseau Tours, Department of Hepatology

    RECRUITING

    Chambray-lès-Tours, 37170, France

  • Center for Liver Tumors Leiden of the Leiden University Medical Center (LUMC)

    RECRUITING

    Leiden, Netherlands

  • Charité - Universitätsmedizin Berlin

    RECRUITING

    Berlin, Germany

  • Cliniques Universitaires Saint-Luc (UCLouvain)

    RECRUITING

    Leuven, Belgium

  • Department for General, Visceral, Pediatric and Transplant Surgery, Universitätsklinikum Aachen

    RECRUITING

    Aachen, Germany

  • Department of Gastroenterology and Hepatology Universitair Ziekenhuis Gent

    RECRUITING

    Ghent, Belgium

  • Department of General, Visceral and Transplantation Surgery, Hospital Universitario Virgen de La Arrixaca

    RECRUITING

    Murcia, Spain

  • Dipartimento di chirurgia generale e specialistica e dei trapianti, Università degli Studi di Torino

    RECRUITING

    Torino, Italy

  • Division of General Surgery & Abdominal Transplantation, Asst Grande Ospedale Metropolitano Niguarda

    RECRUITING

    Milan, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    RECRUITING

    Milan, Italy

  • Gastroenterology and Hepatology, Rotterdam Erasmus Medical Center

    RECRUITING

    Rotterdam, Netherlands

  • Gastroenterology department, Istituto Mediterraneo per i Trapianti Ismett IRCCS

    RECRUITING

    Palermo, Italy

  • Gastroenterology, Hepatology, Infectious Diseases and Endocrinology (GHIE) Medizinische Hochschule Hannover

    RECRUITING

    Hanover, Germany

  • Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Azienda Ospedaliero Universitaria Policlinico di Modena

    RECRUITING

    Modena, Italy

  • Hepatobiliary Surgery and Liver Transplantation, Azienda Ospedaliero Universitaria Pisana (Via Paradisa)

    RECRUITING

    Pisa, Italy

  • Hepatobiliary Surgery and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna

    RECRUITING

    Bologna, Italy

  • Hospital General Universitari València

    RECRUITING

    Valencia, Spain

  • Hospital Henri Mondor, Department of Hepatology

    RECRUITING

    Créteil, 94010, France

  • Hospital Universitario Virgen del Rocío

    RECRUITING

    Seville, Spain

  • Hospital tor Vergata Roma

    RECRUITING

    Roma, Italy

  • Hôpital Erasme Université Libre de Bruxelles

    RECRUITING

    Brussels, Belgium

  • Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsklinikum Münster

    RECRUITING

    Münster, Germany

  • Klinik für Allgemeine, Viszeral- und Transplantationschirurgie, Universitätsklinikum Tübingen

    RECRUITING

    Tübingen, Germany

  • Liver Transplant Unit, Surgery and Oncology, University of Verona

    RECRUITING

    Verona, Italy

  • Ospedale Policlinico San Martino

    RECRUITING

    Genova, Italy

  • UZ Leuven

    RECRUITING

    Leuven, Belgium

  • Università Degli Studi di Udine

    RECRUITING

    Udine, Italy

  • Università Politecnica delle Marche

    RECRUITING

    Ancona, Italy

  • Universität Leipzig

    RECRUITING

    Leipzig, Germany

  • Universitätsklinik für Allgemeinchirurgie, Klinische Abteilung für Transplantation

    RECRUITING

    Vienna, Austria

  • Universitätsklinikum Jena

    RECRUITING

    Jena, Germany

  • Universitätsklinikum Schleswig - Holstein | UKSH · Transplantation Medicine

    RECRUITING

    Kiel, Germany

  • Universitätsklinikum Würzburg

    RECRUITING

    Würzburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.